Targeting p73 in cancer.

Autor: Maas AM; Molecular Oncology, Department of Hematology, Oncology and Immunology, Institute of Molecular Biology and Tumor Research, Philipps-University Marburg, Marburg, Germany., Bretz AC, Mack E, Stiewe T
Jazyk: angličtina
Zdroj: Cancer letters [Cancer Lett] 2013 May 28; Vol. 332 (2), pp. 229-36. Date of Electronic Publication: 2011 Aug 22.
DOI: 10.1016/j.canlet.2011.07.030
Abstrakt: p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. In line with this, genetic studies in mice have confirmed that TAp73 acts as a tumor suppressor. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation.
(Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: